Cargando…

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

BACKGROUND: Aberrant expression of the RON receptor tyrosine kinase, a member of the MET proto-oncogene family, in breast cancer and non-small cell lung cancer (NSCLC) has therapeutic implication. Here we evaluated the efficacy of a novel anti-RON antibody-drug maytansinoid conjugate Zt/g4-DM1 for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Liang, Yao, Hang-Ping, Zhou, Yong-Qing, Zhou, Jianwei, Zhang, Ruiwen, Wang, Ming-Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840490/ https://www.ncbi.nlm.nih.gov/pubmed/27102688 http://dx.doi.org/10.1186/s13046-016-0347-6

Ejemplares similares

Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
por: Feng, Liang, et al.
Publicado: (2016)

Synthesis and Evaluation of Small Molecule Drug Conjugates Harnessing Thioester-Linked Maytansinoids
por: Lo, Chen-Fu, et al.
Publicado: (2022)

Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate
por: Lo, Chen-Fu, et al.
Publicado: (2022)

Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
por: Fujii, Tomohiro, et al.
Publicado: (2021)

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing
por: Costoplus, Juliet A., et al.
Publicado: (2019)

Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction
por: Wang, Ming-Hai, et al.
Publicado: (2013)

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160
por: Lu, Yi, et al.
Publicado: (2008)

A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid
por: Liang, Yanqin, et al.
Publicado: (2017)

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy
por: Tong, Xiang-Min, et al.
Publicado: (2019)

Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment–Drug Conjugates Carrying Maytansinoids DM1 and DM4
por: Kalinovsky, Daniel V., et al.
Publicado: (2023)

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells
por: Yao, Hang-Ping, et al.
Publicado: (2011)

High-Affinity Accumulation of a Maytansinoid in Cells via Weak Tubulin Interaction
por: Goldmacher, Victor S., et al.
Publicado: (2015)

Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
por: Zou, Yi, et al.
Publicado: (2013)

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model
por: Griffin, Patricia, et al.
Publicado: (2023)

RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets
por: Chen, Shao-Long, et al.
Publicado: (2021)

RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin
por: Zhou, Donghui, et al.
Publicado: (2019)

Bulevar del ron
por: Pécheral, Jacques R. (Jacques Renaud), 1908-
Publicado: (1966)

Bulevar del ron
por: Pécheral, Jacques, 1908-
Publicado: (1972)

The healing power of Ron
por: LeBrasseur, Nicole
Publicado: (2003)

Mentors: Ron Kaback
por: Carrasco, Nancy
Publicado: (2019)

Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics
por: Chakedis, Jeffery, et al.
Publicado: (2016)

Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective
por: Dahlgren, David, et al.
Publicado: (2020)

Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines
por: Zhou, Dong-Hui, et al.
Publicado: (2015)

Quick Sketching with Ron Husband
por: Husband, Ron
Publicado: (2014)

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
por: Sheyi, Rotimi, et al.
Publicado: (2022)

Antibody Drug Conjugate Bioinformatics: Drug Delivery through the Letterbox
por: Vlachakis, Dimitrios, et al.
Publicado: (2013)

De la caña al ron
por: Fahrasmane, L.
Publicado: (2005)

Ron Johnston (1941–2020): in memoriam
por: Sidaway, James D., et al.
Publicado: (2020)

Ron's Place: the theatre of (personal) power
por: Slominski, Lisa
Publicado: (2022)

Identification of a New Rhoptry Neck Complex RON9/RON10 in the Apicomplexa Parasite Toxoplasma gondii
por: Lamarque, Mauld H., et al.
Publicado: (2012)

Conformation specific antagonistic high affinity antibodies to the RON receptor kinase for imaging and therapy
por: Yu Koh, Xin, et al.
Publicado: (2022)

MSP-RON Pathway: Potential Regulator of Inflammation and Innate Immunity
por: Huang, Lingtong, et al.
Publicado: (2020)

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics
por: Kumari, Mamta, et al.
Publicado: (2023)

Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics
por: Falck, Georg, et al.
Publicado: (2018)

Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices
por: Qin, Qiuping, et al.
Publicado: (2022)

Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
por: Ma, Qi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bo20qrfre2eqd391ghmsotltkg